Saturday, September 5, 2015
Following up on Howard's and others' posts on the Kim Davis matter: About 25 years ago, I remember being disappointed that some of then-Judge Clarence Thomas's critics insisted they were nervous about -- or, in some cases, were simply snarky about -- statements and writings of his regarding the importance and relevance of the natural law. It seemed to me at the time (and still does) that there was nothing particularly remarkable or weird about these views, considered in the broad context of the American legal and political traditions. But, again, for some of Thomas's critics -- including, interestingly, some of the same people who had, a few years before, professed concern about Judge Bork's statements against the relevance of the natural law -- the fact that Judge Thomas (like Dr. King, etc., etc.) believed that the natural law is real and relevant was thought to be worrisome.
It is similarly disappointing, to me, that some of those (not here!) criticizing Kim Davis's refusal to issue marriage licenses are doing so on the ground that she is not only required by her job description but also -- again, to hear some argue it -- by foundational principles of political morality to comply with every duty imposed on her by the positive law, regardless of any conscientious or religious objections to compliance she might have. This seems too strong. I think we can all think of fairly recent instances in which officials have declined to comply with what seemed to be the positive law duties attached to their offices and avoided the kind of condemnation that Davis has been attracting.
This piece, by Robert Barnes, provides a helpful overview of at least one aspect of the debate ("Legally, 'God's Authority' Is a Tough Issue.") I spoke with Mr. Barnes -- who is, I think, an excellent reporter on legal and constitutional matters -- for a little while yesterday. At one point in the piece, I'm cited in the following way:
. . . Such compromises can be difficult to find. Appeals to “natural law,” and morality, as Davis and Bunning discussed Thursday, are difficult for a judge to assess, said Richard Garnett, a Notre Dame law professor who specializes in religion and the law. . . .
The citation is accurate. It seems to me that, generally speaking, an official who objects on moral grounds to carrying out a positive-law duty should recuse herself or resign (and not refuse to comply with a court order or injunction). That said, my observation about the difficulty any secular/civil judge faces in dealing directly with a claimant's invocation of natural law came in the context of a broader (and fun) conversation in which, among other things, I said that I see nothing spooky or innovative, in the American tradition -- nothing requiring scare-quotes -- about invoking higher-law standards in the course of morally evaluating the positive law. As I discussed with Mr. Barnes, it seems to me that a large part of the human-rights enterprise has involved precisely (even if not always overtly) this kind of evaluation. I believe that the natural law is real and morally binding and that it is entirely appropriate for citizens to do what we reasonably can to make it the case that positive law and policy are consonant with (which, of course, does not mean they should fully capture) the natural law. In other words, to criticize Davis simply for invoking a higher-law standard is, I think, misguided, even if, in the end, we think that Judge Bunning's rulings are correct.
Prof. Mark Rienzi, who is also quoted, put things pretty well:
It is better to base legal arguments on constitutional protections and statutes such as the Religious Freedom Restoration Act, said Mark Rienzi, a Catholic University law professor who is fighting the contraceptive mandate but is not involved in the Davis case.
Judges may have their own ideas of morality, he said, “but I don’t think any of them have the authority to enforce their own moral preferences.”
As the conference draws to a close, there was a roundtable discussion looking to the future of life-patenting:
Martin Gouldstone, Head of Lifesciences Advisory for BDO, reflected on industry concerns over gene patenting. Government funding of medical research has declined in many countries, and regulatory obstacles to approval have increased (for understandable reasons). Estimates of the average cost of bringing a drug to market range from $800M to $1.4B and chances of any particular drug making it to market are very small. Industry is under enormous pressure to replace lost revenue as some big-revenue drugs are going off patent. Companies are beginning to pool resources on research and development and are doing swap deals where companies trade inventories to leverage strengths. Genomics revolution is also driving innovation, and it's just beginning. Challenge is keeping up with speed of technological advances. There is also real danger with the innovation --presented with a future in which 3D printing permits individuals to download and create the bubonic plague, for example, the need for strong regulation is obvious.
Dr. Thana Campos, Van Hugel Institute Research Associate, discussed the phenomenon of universities securing patents for the fruit of its research. She explored the tension between the university mission of disseminating/extending knowledge and the premises of the patent regime. University patents boost university revenue, facilitate more transfer of technology from universities to business partners, and support further innovation and economic development. However, knowledge sharing and spillover are key paths of intellectual development in a university; this is hindered by patents.
Dr. Calum MacKellar, Director of Research at the Scottish Council on Human Bioethics, served as facilitator, and he prompted discussion by asking whether Dr. Frankenstein should have been permitted to patent his creation. Paul Heald pointed out that a patent doesn't give him the right to make the monster or let the monster run amok; it only empowers Dr. Frankenstein to prevent others from making his monster. The problem is not patentability.
A former patent judge asked why churches don't participate in the patent process itself, raising moral concerns as part of the process. A bioethicist speculated that the issues are sufficiently murky morally and technically complicated that churches don't feel comfortable jumping into the process in any particular case. A bishop in the audience observed that, at least in the U.K., people will listen to lay experts more than they will listen to bishops. Another representative of the Church pointed out that the Church is heavily engaged at the level of principle, and he was met with a response that engagement at that level is not sufficient.
Bishop John Sherrington recognized the need for the Church to translate its usual concepts (e.g., common good) into terms that resonate more broadly in these debates. He also reminded participants of Pope Francis's admonition to recognize the real persons before us as the starting point in addressing social issues.
The conversation was robust and relevant. As MoJ's Tom Berg observed in his closing remarks, the Church's rich history of reflection on the meaning of property and economic life, its interest in rigorous and empirical argument, and its global dimension make the Church an essential partner in these conversations.
The Patents on Life conference continues:
Ingrid Schneider, professor of political science at the University of Hamburg, discussed patent governance, ethics and democracy. She sees a legitimacy crisis because of an overexpansion in terms of size and an overreaching of traditional boundaries of patent protection. The patent system is governed by insiders -- a specialized epistemic community with too little responsiveness to the political process and civil society. Blurred boundaries: 1) boundary between discovery and invention (i.e., reflecting a judgment that technology should be accessible to all); and 2) the ordre public and public policy clause (i.e., reflecting a judgment that no one should have access to the technology in question). The ordre public exclusion is designed to function as an ex ante control of the social desirability of an invention. There is a concern that the patent community (applicants, attorneys, examiners, specialist judges) exerts more influence on patent law than the legislature does. Do patent offices view applicants as customers, and if so, what does that mean for the public policies underlying our patent system? She explored the patentability of human embryonic research techniques as an example of these dynamics.
Stephen Colecchi, director of the Office of International Justice and Peace at the United States Conference of Catholic Bishops, spoke about lessons from Catholic social teaching pertaining to life patents. What is the impact of life patents on persons who live at the margins? The Church has expressed concern that technological development has not been accompanied by development of human responsibility. He discussed resources that the American bishops bring to the debate: 1) Catholic social teaching; 2) relationships with the Church in the developing world; 3) experience on the ground working to address challenges in the developing world. He identified four principles to guide the debate: 1) respect for rights of indigenous people; 2) careful balance of property rights and social welfare; 3) concern that commercial interests are favored over common good; and 4) need for transparency. Nevertheless, multinational corporations exert much more influence on IP than Church or other civil society organizations do. It will be critical that the Church continues to engage in a manner that compensates for the power imbalance between richer and poorer nations, and between civil society and the corporate sphere.
Justin Turner, barrister and former member of the Gene Therapy Advisory Committee, discussed the treatment of embryonic stem cells before the European Patent Office. To draw a conclusion about the morality of a patent claim, an examiner must draw on the constitutional traditions of the country as well as international treaties. One must take a broad view. Is terminating an embryo generally contrary to morality? No -- there is no unitary principle that terminating embryonic life is immoral; we have the morning-after pill, embryos are necessarily terminated in the course of IVF, etc. Embryos do not have a right to life for purposes of patent law's morality exemption. Patent claims have been rejected but tribunals have not directly answered question of whether it is contrary to morality. He believes that religious politics are playing an important role in the patent system's treatment of the issue; his concern is that the religious objections are not vented properly in the decisions. The legal tribunals should squarely address whether these patents would be contrary to morality.